Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research
Executive Summary
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
You may also be interested in...
AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action
While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.
Tagrisso Climbs Close To Top Of AstraZeneca Sales Tree
The drug major has presented a set of financials that have comfortably surpassed analyst forecasts and show that its new oncology therapies now make up around 30% of group sales and are growing strongly.
AstraZeneca Rejig Brings Baselga On Board
A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.